Abstract CT100: Survival outcomes in a randomized phase 2 of Bria-IMT : An allogeneic whole cell cancer vaccine

Saranya Chumsri; Chaitali Nangia; Minal Barve; Kendrith Rowland; Ralph Boccia; John Knecht; Blaise Bayer; Marcela Salgado; Tamar Aghajanian; William V. Williams; Charles Wiseman; Giuseppe Del Priore; Carmen Calfa

doi:10.1158/1538-7445.AM2025-CT100

Back

Abstract CT100: Survival outcomes in a randomized phase 2 of Bria-IMT : An allogeneic whole cell cancer vaccine

Journal article

Peer reviewed

Abstract CT100: Survival outcomes in a randomized phase 2 of Bria-IMT : An allogeneic whole cell cancer vaccine

Saranya Chumsri, Chaitali Nangia, Minal Barve, Kendrith Rowland, Ralph Boccia, John Knecht, Blaise Bayer, Marcela Salgado, Tamar Aghajanian, William V. Williams, …

Cancer research (Chicago, Ill.), Vol.85(8_Supplement_2), pp.CT100-CT100

2025-04-25

DOI: https://doi.org/10.1158/1538-7445.AM2025-CT100

Appears in Miller School of Medicine - Latest Publications

Metrics

2 Record Views

Details

Title: Abstract CT100: Survival outcomes in a randomized phase 2 of Bria-IMT : An allogeneic whole cell cancer vaccine
Creators: Saranya Chumsri - Nemours Children’s Clinic
Chaitali Nangia
Minal Barve - Sarah Cannon
Kendrith Rowland - Urbana University
Ralph Boccia - Center for Cancer and Blood Disorders
John Knecht
Blaise Bayer
Marcela Salgado
Tamar Aghajanian
William V. Williams
Charles Wiseman
Giuseppe Del Priore - Morehouse School of Medicine
Carmen Calfa - University of Miami
Publication Details: Cancer research (Chicago, Ill.), Vol.85(8_Supplement_2), pp.CT100-CT100
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991032662026602976